GlassScriptPhysician profile
Justin J Chow
NPI 1700899622
$6,953.78
in general payments reported to CMS, 2019-2025
28 companies · $426 in 2025
The $426 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $584 · 2020: $125 · 2021: $1,022 · 2022: $1,953 · 2023: $1,872 · 2024: $972 · 2025: $426.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,270.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,269.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $891.67 | 2022-2024 | Pomalyst, Reblozyl |
| Astrazeneca Pharmaceuticals LP | $869.96 | 2020-2023 | Calquence |
| Abbvie INC. | $492.63 | 2022-2025 | Venclexta, Epkinly, Dalvance |
| Janssen Pharmaceuticals, INC | $484.28 | 2019-2021 | |
| Boston Scientific Corporation | $463.28 | 2022-2025 | General - Balloon Catheters, Avvigo Guidance System |
| Janssen Biotech, INC. | $421.87 | 2022 | |
| Abbott Laboratories | $392.14 | 2024 | Amplatzer Talisman, Amplatzer Amulet, Mitraclip |
| Genzyme Corporation | $309.84 | 2021 | |
| Novartis Pharmaceuticals Corporation | $215.74 | 2019 | |
| Pharmacosmos Therapeutics INC. | $212.79 | 2021-2023 | Monoferric |
| Grifols USA, LLC | $201.12 | 2023-2024 | Gamunex-C, Hyperrab |
| Pharmacyclics LLC, An Abbvie Company | $177.58 | 2022-2023 | Epkinly, Imbruvica |
| W. L. Gore & Associates, INC. | $152.86 | 2023 | Gore Cardioform Septal Occluder |
| Alexion Pharmaceuticals, INC. | $125.00 | 2023 | |
| Jazz Pharmaceuticals INC. | $125.00 | 2023 | Zepzelca |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmaessentia USA Corporation | $125.00 | 2023 | Besremi |
| Abiomed | $125.00 | 2024 | Impella |
| Glaxosmithkline, LLC. | $124.99 | 2021 | |
| Amarin Pharma, INC. | $124.99 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $124.99 | 2022 | |
| Incyte Corporation | $123.33 | 2023 | Monjuvi |
| Portola Pharmaceuticals, LLC | $122.63 | 2019 | |
| Beigene USA, INC. | $118.14 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $107.95 | 2022 | |
| Shockwave Medical, INC | $101.42 | 2025 | |
| Exelixis INC. | $98.63 | 2021 | |
| Amgen INC. | $92.87 | 2022 | |
| Janssen Scientific Affairs, LLC | $28.08 | 2025 | Darzalex, Carvykti, Talvey |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Justin Chow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.